Evidence map›Paper›PMID 20434954›Full record

ReviewTrends in molecular medicine2010

MiR-210--micromanager of the hypoxia pathway.

Xin Huang, Quynh-Thu Le, Amato J Giaccia

Abstract readReview
In one paragraph

Review in Trends in molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 3 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 3 syntheses or guidelines pooled it, 377 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. CAP-CD56Bioactive materials · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xin HuangMagee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Quynh-Thu Le
Amato J Giaccia
Stanford University · USUniversity of Pittsburgh · US

Funding

TUMOR HYPOXIA--MOLECULAR STUDIES &CLINICAL EXPLOITATIONP01CA067166 · NCI · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN · 1996 to 2017
$25.5M
Defining Molecular Markers for Tumor HypoxiaR01CA118582 · NCI · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN · 2006 to 2010
$2.2M
Hypoxia and Gene RepressionR37CA088480 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2010 to 2014
$1.6M
NCI NIH HHS P01 CA067166NCI NIH HHS P01-CA67166NCI NIH HHS R01 CA118582NCI NIH HHS R01-CA118582NCI NIH HHS R37 CA088480
6 · The paper itself

Abstract

Hypoxia inducible factors (HIFs) regulate a variety of genes to prepare cells to adapt and survive under a hypoxic environment. Recently, microRNAs (miRNAs) have emerged as a new class of genes regulated by HIFs in response to hypoxia, of which miR-210 is the most consistently and predominantly upregulated miRNA. Functional studies have demonstrated that miR-210 is a versatile gene that regulates many aspects of hypoxia pathways, both in physiological and malignant conditions. Here, we summarize recent findings on the mechanism of hypoxia regulation of miR-210 expression and its multifaceted biological functions in normal physiological and malignant conditions, and discuss the challenges we face in elucidating the biological functions of miR-210 and exploring its potential use for therapeutics.

Indexed as

AnimalsHumansHypoxiaMicroRNAsModels, BiologicalSignal TransductionMicroRNAsMIRN210 microRNA, human

Identifiers

PMID20434954
PMCPMC3408219
OpenAlexW2089467855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.